Royalties payable Royalties Payable Represents the amount of royalties payable. Business Acquisition [Axis] Business Acquisition [Axis] Increase (Decrease) in Stockholders' Equity Increase (Decrease) in Stockholders' Equity [Roll Forward] Net income Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Projected cash flows period Fair Value Inputs Cash Flows Estimated Period Period of time used to measure cash flows to find the present value of an amount to be paid or received in the future as an input to measure fair value. Deferred income tax asset Deferred Income Tax Assets, Net Entity Address, Postal Zip Code Entity Address, Postal Zip Code Finance lease right-of-use assets, net Finance Lease, Right-of-Use Asset, after Accumulated Amortization Square footage Area of Real Estate Property Syros Pharmaceuticals, Inc. Syros Pharmaceuticals, Inc. Represents details pertaining to Syros Pharmaceuticals, Inc with whom we have entered into a target discovery, research collaboration and option agreement. Number of program targets Number Of Program Targets Represents the number of program targets identified. Property, Plant and Equipment [Abstract] Property, Plant and Equipment [Abstract] Preferred stock, shares outstanding Preferred Stock, Shares Outstanding Issuance of shares of Common Stock upon exercise of stock options and settlement of employee restricted stock units and performance shares, net of shares withheld for taxes and shares of Common Stock under the ESPP Stock Issued During Period Value Stock Options and Restricted Stock Units Exercised and Employee Stock Purchase Plan Value stock issued during the period as a result of the exercise of stock options and restricted stock units and the aggregate change in value for stock issued during the period as a result of employee stock purchase plan. Fair market value of our long term investments Investments, Fair Value Disclosure Financing lease liabilities Finance Lease, Liability Property and Equipment, gross Property, Plant and Equipment, Gross Office Building in Wilmington, Delaware Office Building in Wilmington, Delaware Represents information relating to the office building located in Wilmington, Delaware. Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Released (in shares) Share Based Compensation Arrangement By Share Based Payment Award, Equity Instruments Other Than Options, Released In Period Represents the number of shares of employee compensation programs, other than options, released during the period. Target selection and option exercise fee payment License Agreement Target Selection and Option Exercise Fee Payments Represents the target selection and option exercise fee payments to be made under the license agreement. Stock purchase agreement Stock purchase agreement Represents stock purchase agreement. Fair Value Measurement [Domain] Fair Value Measurement [Domain] Financial Instruments [Domain] Financial Instruments [Domain] Operating lease right-of-use assets Operating lease right-of-use assets Contractual agreement that stipulates the lessee pay the lessor for use of an asset under operating lease. Statistical Measurement [Domain] Statistical Measurement [Domain] Options exercised (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Upfront payment under license agreement License Agreement Upfront Payment Amount Paid Represents the amount of the upfront payment made under the license agreement. Sale and maturities of marketable securities Proceeds from Sale and Maturity of Marketable Securities Share-based Payment Arrangement [Abstract] Share-Based Payment Arrangement [Abstract] Current year expected contributions total Defined Benefit Plan, Expected Future Employer Contributions, Current Fiscal Year One-time benefit from associated valuation allowance Income Tax Expense (Benefit), Continuing Operations, Adjustment of Deferred Tax (Asset) Liability Additional paid-in capital Additional Paid in Capital, Common Stock Period of notice for termination of license agreement License Agreement, Termination Notice, Period Represents the notice period for the termination of license agreement. Net periodic benefit cost Defined Benefit Plan, Net Periodic Benefit Cost (Credit) Schedule of inventory Schedule of Inventory [Table Text Block] Tabular disclosure of carrying amount of inventories as of the balance sheet date. Other, net Other Noncash Income (Expense) Real Estate Properties [Domain] Real Estate Properties [Domain] Net income Net income Net Income (Loss) Attributable to Parent Measurement Input Type [Domain] Measurement Input Type [Domain] Potential common shares excluded from diluted net income (loss) per share computation ( in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Subsequent Event Type Subsequent Event Type [Axis] Amortization of prior service cost Defined Benefit Plan, Amortization of Prior Service Cost (Credit) Equity Component [Domain] Equity Component [Domain] Number of shares awarded for each RSU (in shares) Share Based Compensation Arrangement by Share Based Payment Award Number of Shares Per Restricted Stock Units Represents the number of shares awarded for each restricted share units. Subsequent Event Type Subsequent Event Type [Domain] Measurement Input, Discount Rate Measurement Input, Discount Rate [Member] Total assets Assets, Fair Value Disclosure Percentage of units vesting at the end of each calendar year (as a percent) Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage Investment, Name [Domain] Investment, Name [Domain] Supplemental Schedule of Cash Flow Information Supplemental Cash Flow Information [Abstract] Cancelled (in USD per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Payment of contingent consideration Payment of Contingent Consideration The cash outflow with regard to the contingent consideration during the period. Number of operating segments Number of Operating Segments PEMAZYRE PEMAZYRE Represents information pertaining to PEMAZYRE (pemigatinib), a selective fibroblast growth factor receptor (FGFR) inhibitor, for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with an FGFR2 fusion or other rearrangement as detected by an FDA-approved test. Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Customer D Customer D [Member] Represents information pertaining to the customer D. Entity Address, State or Province Entity Address, State or Province Fair Value, Inputs, Level 1 Fair Value, Inputs, Level 1 [Member] Employee Stock Employee Stock [Member] Milestone payments for net sales of product License Agreement, Milestone on Net Sales of Product License Agreement, Milestone on Net Sales of Product Clinical related costs Accrued Clinical Related Costs Current Carrying value as of the balance sheet date of obligations incurred through that date and payable for clinical related costs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). Award Type [Axis] Award Type [Axis] Amortization of actuarial losses Defined Benefit Plan, Benefit Obligation, Actuarial Gain (Loss) Net cash provided by operating activities Net Cash Provided by (Used in) Operating Activities Operating lease liabilities Operating Lease, Liability, Current Summary of marketable securities portfolio Debt Securities, Available-for-Sale [Table Text Block] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Costs and expenses: Costs and Expenses [Abstract] Options cancelled (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period Legal Entity [Axis] Legal Entity [Axis] Liability Class [Axis] Liability Class [Axis] Additional milestone payments under the license agreement License Agreement Additional Milestone Payments Represents the additional milestone payments to be made under the license agreement. Total liabilities Liabilities Stock compensation Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Geographical [Axis] Geographical [Axis] Total inventory Inventory Net Current and Noncurrent Represents the aggregate carrying amount of current and noncurrent portion, net of valuation reserves and allowances, as of the balance sheet date of inventories. Cash flows from investing activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Renewal term of agreement to rent Lessee, Finance Lease, Renewal Term Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Risks and Uncertainties [Abstract] Risks and Uncertainties [Abstract] Marketable securities-amortized cost Debt Securities, Available-for-Sale, Amortized Cost, Current Purchase of common stock under Stock Purchase Agreement (in shares ) Purchase of common stock under stock purchase agreement in shares Represents the purchase of common stock under Stock Purchase Agreement. Schedule of property and equipment, net Property, Plant and Equipment [Table Text Block] Marketable securities—available-for-sale (amortized cost $292,941 and $291,871 as of September 30, 2022 and December 31, 2021, respectively; allowance for credit losses $0 as of September 30, 2022 and December 31, 2021) Debt Securities, Available-for-Sale, Current Preferred stock, shares issued Preferred Stock, Shares Issued Document Type Document Type Stock Options Weighted Average Price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Stock Conversion Description [Axis] Stock Conversion Description [Axis] RSU and PSU Activity Shares Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Concentration Risk Benchmark [Domain] Concentration Risk Benchmark [Domain] Product and Service [Domain] Product and Service [Domain] Entity Shell Company Entity Shell Company Upfront and immediate milestone payment to be received under license agreement License Agreement, Upfront Payment and Immediate Milestone Payment to be Received Represents the upfront and immediate milestone payment received under the license agreement. Accrued and other liabilities Increase (Decrease) in Accrued Liabilities Concentration Risk [Table] Concentration Risk [Table] Value of shares acquired Equity Method Investment, Quoted Market Value Options, RSUs and PSUs granted (in shares) Share Based Compensation Arrangement by Share Based Payment Award Number of Shares Granted Number of shares granted under an established share-based compensation plan. Financial Instrument [Axis] Financial Instrument [Axis] Subsequent Event Subsequent Event [Member] Document Period End Date Document Period End Date Share-based Payment Arrangement, Tranche One Share-Based Payment Arrangement, Tranche One [Member] Total assets Assets Net income per share: Earnings Per Share [Abstract] Earnings Per Share [Abstract] Income Statement Location [Axis] Income Statement Location [Axis] Weighted-average fair value assumptions Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology [Abstract] Construction in progress Construction Payable, Current Antidilutive Securities [Axis] Antidilutive Securities [Axis] Performance Shares Performance Shares [Member] Accrued and other current liabilities Total accrued and other current liabilities Accrued Liabilities, Current Credit Concentration Risk Credit Concentration Risk [Member] Exercised (in USD per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Investment in Syndax Investment in Syndax Represents investment information pertaining to Syndax Pharmaceuticals Inc. Net cash provided by (used in) financing activities Net Cash Provided by (Used in) Financing Activities Accounting Policies [Abstract] Accounting Policies [Abstract] Long-Term Investments Fair market long term investments Long-Term Investments Future contingent discovery milestones Future contingent discovery milestones Represents information pertaining to future contingent discovery milestone. TABRECTA TABRECTA Represents information pertaining to TABRECTA, treatment of adult patients with metastatic NSCLC whose tumors have a mutation that leads to MET exon 14 skipping (METex14). Accrued compensation Employee-related Liabilities, Current Income before provision for income taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Stockholders’ equity: Stockholders' Equity Attributable to Parent [Abstract] Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Net Income Per Share Earnings Per Share [Text Block] Customer [Axis] Customer [Axis] Interest cost Defined Benefit Plan, Interest Cost Finance lease liabilities Finance Lease, Liability, Noncurrent Syndax Syndax Represents member information pertaining to Syndax Pharmaceuticals Inc. License Agreements Related Party Transaction [Line Items] Award Type [Domain] Award Type [Domain] Vesting period of recognition of the unrecognized compensation cost of nonvested awards Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Proceeds from issuance of common stock under stock plans Proceeds from Stock Plans Computer Equipment Computer Equipment [Member] Entity Registrant Name Entity Registrant Name Schedule of valuation assumptions used for valuation of fair value of stock compensation granted Schedule of Share Based Payment Award, Stock Options and Employee Stock Purchase Plan Valuation Assumptions [Table Text Block] Tabular disclosure of the significant assumptions used during the year to estimate the fair value of employee stock options plan and employee stock purchase plans, including, but not limited to: (a) expected term, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions. Subsequent Events Subsequent Events [Text Block] Percentage of profit (losses) Percentage of Profits (Losses) Represents the percentage of profits (losses). JAKAVI JAKAVI Represents information pertaining to JAKAVI (ruxolitinib), an oral Janus associate kinase (JAK) inhibitor sold outside the United State of America. Dividend yield (as a percent) Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate Entity Address, City or Town Entity Address, City or Town Employee Benefit Plans Retirement Benefits [Text Block] Number of additional preclinical discovery programs License Agreement, Number of Additional Preclinical Discovery Programs Represents the number of additional preclinical discovery programs. Increase in unrecognized tax benefits Unrecognized Tax Benefits, Period Increase (Decrease) Principles of Consolidation Consolidation, Policy [Policy Text Block] Minimum Minimum [Member] Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Entity Emerging Growth Company Entity Emerging Growth Company Product royalty revenues Royalty [Member] Common stock, par value (in USD per share) Common Stock, Par or Stated Value Per Share Raw materials Inventory, Raw Materials, Net of Reserves Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Investment, Name [Axis] Investment, Name [Axis] Fair Value of Financial Instruments Fair Value Disclosures [Text Block] Per share price (In USD per share) Share Price Trading Symbol Trading Symbol Entity File Number Entity File Number MacroGenics MacroGenics Represents details pertaining to MacroGenics with whom we have entered into an exclusive global collaboration and license agreement. Development, Regulatory and Commercialization Milestones Development, Regulatory and Commercialization Milestones Represents development regulatory and commercialization milestones. Other Comprehensive Income (Loss) Other Comprehensive Income (Loss) [Member] Research and development Research and development expense Research and Development Expense Equipment Equipment [Member] Fair Value by Liability Class [Domain] Fair Value by Liability Class [Domain] Finance lease, lease incentive receivable Finance Lease, Lease Incentive Receivable The amount of lease incentive receivable from landlord under finance leases. Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Restricted Stock Units (RSUs) Restricted Stock Units (RSUs) [Member] Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Axis] ICLUSIG ICLUSIG Represents information pertaining to ICLUSIG, a kinase inhibitor. Use of Estimates Use of Estimates, Policy [Policy Text Block] Cash and cash equivalents Cash and Cash Equivalents, Fair Value Disclosure Other comprehensive loss: Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract] Number of independent programs License Agreement, Maximum Number Of Independent Programs Represents the maximum number of independent programs encompassed under the collaboration agreement. Accounts payable Increase (Decrease) in Accounts Payable Organization and Business Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block] Balance at the beginning of the period Balance at the end of the period Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value Percentage of concentration risk Concentration Risk, Percentage Subsequent Events [Abstract] Income Taxes Income Tax Disclosure [Text Block] Finished goods Inventory, Finished Goods, Net of Reserves Debt Securities, Trading, and Equity Securities, FV-NI [Table] Debt Securities, Trading, and Equity Securities, FV-NI [Table] ARIAD ARIAD Represents information pertaining to ARIAD Pharmaceuticals. Basic (in USD per share) Basic net income per share ( in USD per share) Earnings Per Share, Basic Achievement of Milestone [Domain] Achievement of Milestone [Domain] Different categories of achievement of milestones. Amortized Cost Amortized Cost Debt Securities, Available-for-Sale, Amortized Cost, Excluding Accrued Interest, after Allowance for Credit Loss Concentration Risk Type [Domain] Concentration Risk Type [Domain] Counterparty Name [Domain] Counterparty Name [Domain] Sales allowances Provision for Loss on Contracts Total stockholders’ equity Beginning Balance Ending Balance Stockholders' Equity Attributable to Parent Leased assets obtained in exchange for new finance lease liabilities Right-of-Use Asset Obtained in Exchange for Finance Lease Liability Vesting [Domain] Vesting [Domain] Marketable securities-allowance for credit losses Debt Securities, Available-for-Sale, Allowance for Credit Loss Entity Interactive Data Current Entity Interactive Data Current Shares divested (in shares) Number of shares in underwritten public offering (in shares) Sale of Stock, Number of Shares Issued in Transaction Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] MorphoSys AG MorphoSys AG Represents member information pertaining to MorphoSys AG. Changes in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Schedule of roll forward of Level 3 liabilities Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Portion at Fair Value Measurement Portion at Fair Value Measurement [Member] Accumulated Deficit Retained Earnings [Member] Commercialization Milestones Commercialization Milestones Represents information pertaining to certain commercialized events on the basis of which certain milestones are achieved. Pre September 2022 -Stock Split Shares Pre September 2022 -Stock Split Shares [Member] Pre September 2022 -Stock Split Shares InnoCare InnoCare Represents information pertaining to InnoCare Pharma Limited ("InnoCare"). Common Stock Common Stock [Member] Profit sharing (as a percent) Collaboration Agreement Profit Sharing Percentage Represents the percentage of profits and losses shared under the collaboration agreement. Other comprehensive loss Other comprehensive income (loss) Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent Issuance of shares of Common Stock upon exercise of stock options and settlement of employee restricted stock units, net of shares withheld for taxes Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture Released (in USD per share) Share Based Compensation Arrangement By Share Based Payment Award, Equity Instruments Other Than Options, Released Intrinsic Value Per share weighted average intrinsic value of equity-based compensation awards released. Excludes stock and unit options. Beginning Balance (in shares) Ending Balance (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant Acquisition-related contingent consideration Business Combination, Contingent Consideration, Liability Statement [Table] Statement [Table] OPZELURA OPZELURA Represents information pertaining to OPZELURA (ruxolitinib) cream, a novel cream formulation of Incyte's selective JAK1/JAK2 inhibitor ruxolitinib. Document Quarterly Report Document Quarterly Report Current assets: Assets, Current [Abstract] Upfront payment received under license agreement License Agreement, Upfront Payment Received Represents the upfront payment received under the license agreement. Defined contribution expense Defined Contribution Plan, Cost Statistical Measurement [Axis] Statistical Measurement [Axis] Sale of long term investments Proceeds from Sale of Long-Term Investments Accumulated deficit Retained Earnings (Accumulated Deficit) Liability Liability [Member] Purchases of marketable securities Payments to Acquire Marketable Securities Equity Components [Axis] Equity Components [Axis] Fair Value, Recurring Fair Value, Recurring [Member] Incyte Incyte Represents member information pertaining to Incyte. Document Fiscal Year Focus Document Fiscal Year Focus Cash flows from operating activities: Net Cash Provided by (Used in) Operating Activities [Abstract] Statement Statement [Line Items] Payment of finance lease liabilities Finance Lease, Principal Payments Period of lower average per unit cost of materials Period Of Deviation From Average, Cost Of Goods Sold Represents the length of time in which cost of goods sold will deviate from average due to unusual and/or infrequent conditions. Acquisition-related contingent consideration Business Combination, Contingent Consideration, Liability, Current Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Selling, general and administrative Selling, General and Administrative Expense Agenus Agenus Represents details pertaining to Agenus with whom we have entered into a License, Development and Commercialization Agreement. Nimble Nimble Represents information pertaining to Nimble. (Gain) loss on change in fair value of acquisition-related contingent consideration Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability Royalties Accrued Royalties, Current Product revenues, net Product [Member] Milestone and contract revenues Milestone and contract revenues Represents information pertaining to milestone and contract revenues. Accumulated Other Comprehensive Loss AOCI Attributable to Parent [Member] Capital expenditures Payments to Acquire Productive Assets Document Transition Report Document Transition Report Local Phone Number Local Phone Number Building and leasehold improvements Building and leasehold improvements Represents information relating to building and leasehold improvements. Schedule of option activity under the 2010 Stock Plan Share-Based Payment Arrangement, Option, Activity [Table Text Block] Income from operations Operating Income (Loss) Inventory Increase (Decrease) in Inventories Calithera Calithera Represents details pertaining to our long-term investment in Calithera Biosciences, Inc with whom we have entered into a License and Commercialization Agreement. Recent Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Prepaid expenses and other assets Increase (Decrease) in Prepaid Expense and Other Assets Accrued and other liabilities Accrued Liabilities and Other Liabilities Common stock, shares outstanding Common Stock, Shares, Outstanding Goodwill Goodwill Office Building in Morges, Switzerland Office Building in Morges, Switzerland Represents information relating to the office building located in Morges, Switzerland. Long-Lived Tangible Asset [Axis] Long-Lived Tangible Asset [Axis] Adjustments to reconcile net income to net cash provided by operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Provision for income taxes Income tax (benefit) expense Income Tax Expense (Benefit) Geographical [Domain] Geographical [Domain] Customer C Customer C [Member] Represents information pertaining to the customer C. Valuation allowance Deferred Tax Assets, Valuation Allowance Debt securities (government) Debt securities (government) Debt securities issued by government or corporate business, banks and other entities with a promise of repayment. Preferred stock, par value (in USD per share) Preferred Stock, Par or Stated Value Per Share Income Statement [Abstract] Income Statement [Abstract] Additional Paid-in Capital Additional Paid-in Capital [Member] Balance Sheet Location [Domain] Balance Sheet Location [Domain] Document Fiscal Period Focus Document Fiscal Period Focus Basic Net Income (Loss) Per Share Earnings Per Share, Basic [Abstract] Diluted (in shares) Weighted average shares used to compute diluted net income per share ( in shares) Weighted Average Number of Shares Outstanding, Diluted Less accumulated depreciation and amortization Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Concentrations of Credit Risk and Current Expected Credit Losses Concentration Risk Disclosure [Text Block] Average expected life (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Real Estate Property Ownership [Axis] Real Estate Property Ownership [Axis] Summary of marketable security portfolio Debt Securities, Available-for-Sale [Line Items] Accounts Receivable Accounts Receivable [Member] Options, RSUs and PSUs cancelled (in shares) Share Based Compensation Arrangement by Share Based Payment Award Number of Shares Canceled Number of shares canceled under an established share-based compensation plan. Common stock, $0.001 par value; 400,000,000 shares authorized; 222,454,839 and 221,084,433 shares issued and outstanding as of September 30, 2022 and December 31, 2021, respectively Common Stock, Value, Issued Cancelled (in USD per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Intrinsic Value, Amount Per Share Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] Schedule of antidilutive securities excluded from the computation of earnings per share Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Preferred stock, shares authorized Preferred Stock, Shares Authorized Net income per share Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items] Cash, cash equivalents, restricted cash and investments at beginning of period Cash, cash equivalents, restricted cash and investments at end of period Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Ownership (in shares) Investment Owned, Balance, Shares Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Current liabilities: Liabilities, Current [Abstract] Basic net income Net Income (Loss) Available to Common Stockholders, Basic Common stock, shares issued Common Stock, Shares, Issued Milestone payment made under license agreement License Agreement Milestone Payment Amount Paid Represents the amount of the milestone payment made under the license agreement. Concentration of risk Concentration Risk [Line Items] TABRECTA Royalty Revenues TABRECTA Royalty Revenues Represents information pertaining to TABRECTA royalty revenues, treatment of adult patients with metastatic NSCLC whose tumors have a mutation that leads to MET exon 14 skipping (METex14). Inventory incurred prior to FDA approval Inventory, Recorded as Research and Development Expense Represents the aggregate carrying amount of current and noncurrent portion, net of valuation reserves and allowances, as of the balance sheet date of inventories recorded as research and development expense. Unpaid purchases of property and equipment Capital Expenditures Incurred but Not yet Paid Income Statement Location [Domain] Income Statement Location [Domain] GVHD GVHD Represents information pertaining to GVHD, an Graft-Versus-Host Disease field. Finance lease liabilities Finance Lease, Liability, Current Fair value of financial instruments Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Amendment Flag Amendment Flag Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities Comprehensive income Comprehensive Income (Loss), Net of Tax, Attributable to Parent Schedule of fair value of liabilities measured on recurring basis Fair Value, Liabilities Measured on Recurring Basis [Table Text Block] Construction in Progress Construction in Progress [Member] Entity Current Reporting Status Entity Current Reporting Status Other current liabilities Other Liabilities, Current Other assets, net Other Assets, Noncurrent Royalty-bearing product GITR, OX40 and one undisclosed target Royalty-bearing product GITR, OX40 and one undisclosed target Represents the royalty-bearing product GITR, OX40 and one undisclosed target. Depreciation and amortization Depreciation, Depletion and Amortization Profit (loss) sharing ratio Collaboration Agreement Profit Loss Sharing Ratio Ratio of sharing profit and losses under the collaboration agreement. Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] Estimated Fair Value Debt Securities, Available-for-Sale, Excluding Accrued Interest JAPAN JAPAN Issuance of shares of Common Stock under the ESPP Stock Issued During Period, Shares, Employee Stock Purchase Plans Counterparty Name [Axis] Counterparty Name [Axis] Outstanding at the beginning of the period (in shares) Outstanding at the end of the period (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Share conversion Subsidiary Stock, Conversion Ratio Number of parent common shares issuable upon conversion for each share of subsidiary stock to be converted. Accrued and Other Current Liabilities Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block] Sales and marketing Accrued Marketing Costs, Current IPO IPO [Member] Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Zai Lab Ltd Zai Lab Ltd Represents the collaboration and license agreement with Zai Lab Ltd. Basis of presentation Basis of Accounting, Policy [Policy Text Block] Effect of exchange rates on cash, cash equivalents, restricted cash and investments Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations Property and equipment, net Property and equipment, net Property, Plant and Equipment, Net Office Equipment Office Equipment [Member] Change in fair value of contingent consideration Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings Share-based Payment Arrangement, Option Share-Based Payment Arrangement, Option [Member] Defined benefit pension gain, net of tax Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax Volatility (as a percent) Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate Contingent consideration earned during the period but not yet paid Business Combination, Contingent Consideration Arrangements, Change In Amount Of Contingent Consideration Liability, Consideration Earned Amount of decrease in the value of a contingent consideration liability attributable to consideration earned by the acquiree in a business combination. Development and Regulatory Milestones Development and Regulatory Milestones Represents information pertaining to certain development and regulatory events on the basis of which certain milestones are achieved. Cancelled (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period Other income (expense), net Other Nonoperating Income (Expense) Balance Sheet Location [Axis] Balance Sheet Location [Axis] Common stock, shares authorized Common Stock, Shares Authorized Acquisition-related contingent consideration Business Combination, Contingent Consideration, Liability, Noncurrent Schedule of Related Party Transactions, by Related Party [Table] Schedule of Related Party Transactions, by Related Party [Table] Land in Y-PARC, Switzerland's largest technology park, Yverdon Land in Y-PARC, Switzerland's largest technology park, Yverdon Represents information pertaining to land located with Y-PARC, Switzerland's largest technology park in Yverdon. JAKAFI JAKAFI JAKAFI Represents information pertaining to JAKAFI (ruxolitinib), an oral Janus associate kinase (JAK) inhibitor sold within the United State of America. Location of costs excluding the service component Defined Benefit Plan, Net Periodic Benefit Cost (Credit) Excluding Service Cost, Statement of Income or Comprehensive Income [Extensible Enumeration] Statement of Comprehensive Income [Abstract] Statement of Comprehensive Income [Abstract] Maximum Maximum [Member] Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax Villaris Villaris [Member] Villaris OLUMIANT Royalty Revenues OLUMIANT Royalty Revenues Represents information pertaining to OLUMIANT royalty revenues, a treatment of adults with moderately-to-severely active rheumatoid arthritis. Share-Based Payment Arrangement Share-Based Payment Arrangement [Member] Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Total current assets Assets, Current Income taxes paid Income Taxes Paid, Net Entity Small Business Entity Small Business Measurement Basis [Axis] Measurement Basis [Axis] Restricted cash and investments Restricted Cash and Investments, Noncurrent Measurement Frequency [Domain] Measurement Frequency [Domain] Schedule of net periodic benefit cost Schedule of Net Benefit Costs [Table Text Block] Revenues: Revenues [Abstract] Funding of future development costs (as a percent) License Agreement Percentage of Future Global Development Costs Funded Represents the percentage of future global development costs funded under the license agreement. Royalty payments on future global net sales (as a percent) Percentage Of Royalty Rate Payments Represents range of tiered, double-digit royalty payments on future global sales if product is successfully commercialized. Schedule of fair value of assets measured on recurring basis Fair Value, Assets Measured on Recurring Basis [Table Text Block] Net Unrealized Losses Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain (Loss), before Tax Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Unrecognized compensation cost for nonvested option (in dollars) Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount Option Activity Shares Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward] Property and Equipment, net Property, Plant and Equipment Disclosure [Text Block] Long-Lived Tangible Asset [Domain] Long-Lived Tangible Asset [Domain] Accounts receivable Increase (Decrease) in Accounts Receivable Title of 12(b) Security Title of 12(b) Security Options to extend Lessee, Finance Lease, Existence of Option to Extend [true false] Total costs and expenses Costs and Expenses Payables and Accruals [Abstract] Payables and Accruals [Abstract] Subsequent Event [Line Items] Subsequent Event [Line Items] Options granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures Issuance of shares of Common Stock upon exercise of stock options and settlement of employee restricted stock units and performance shares Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture Purchase price Payments to Acquire Real Estate Selling, General and Administrative Expenses Selling, General and Administrative Expenses [Member] Initial lease term Lessee, Finance Lease, Term of Contract LIABILITIES AND STOCKHOLDERS’ EQUITY Liabilities and Equity [Abstract] Estimate of Fair Value Measurement Estimate of Fair Value Measurement [Member] Foreign currency translation loss Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent Granted (in USD per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Fair Value, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Shares used in computing net income per share: Weighted Average Number of Shares Outstanding, Diluted [Abstract] Gross proceeds from sale of stock Sale of Stock, Consideration Received on Transaction Inventory Inventories - current Inventory, Net Accrued and other current liabilities Accrued and other current liabilities Primary financial statement caption encompassing accrued and other current liabilities. Accounts payable Accounts Payable, Current TABRECTA PROD SERV TABRECTA PRODUCT AND SERVICES [Member] TABRECTA PRODUCT AND SERVICES Revenue, Product and Service Benchmark Revenue, Product and Service Benchmark [Member] Entity Filer Category Entity Filer Category Basic (in shares) Weighted average common shares outstanding (in shares) Weighted Average Number of Shares Outstanding, Basic UNITED STATES UNITED STATES Accrued and Other Current Liabilities Accrued Liabilities, Current [Abstract] Ownership percentage (as a percent) Equity Method Investment, Ownership Percentage Stock compensation expense Share-Based Payment Arrangement, Expense Commitments and contingencies (Note 14) Commitments and Contingencies Security Exchange Name Security Exchange Name Exercise prices of options outstanding (in USD per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Accounts receivable Accounts Receivable, after Allowance for Credit Loss Preferred stock, $0.001 par value; 5,000,000 shares authorized; none issued or outstanding Preferred Stock, Value, Issued Amended stock purchase agreement Amended stock purchase agreement Represents amended stock purchase agreement. Achievement of Milestone [Axis] Achievement of Milestone [Axis] Represents information by different categories of achievement of milestones. Issuance of shares of Common Stock for services rendered Stock Issued During Period, Value, Issued for Services Property and equipment, net Property, Plant and Equipment [Line Items] Total revenues Revenues Revenue from Contract with Customer, Excluding Assessed Tax Collaboration Partner A, B, C and D Collaboration Partner A, B, C and D Represents information pertaining to both the Collaboration partners A, B, C and D. Employer service cost Defined Benefit Plan, Service Cost Cover [Abstract] Cover [Abstract] Tafasitamab Product and Service Tafasitamab Product and Service [Member] Tafasitamab Product and Service Fair Value, Inputs, Level 3 Fair Value, Inputs, Level 3 [Member] Purchase of long term investments Payments to Acquire Long-Term Investments Stock Compensation Share-Based Payment Arrangement [Text Block] Allowance for doubtful accounts Accounts Receivable, Allowance for Credit Loss tafasitamab tafasitamab Represents information pertaining to tafasitamab. Work-in-process Inventory, Work in Process, Net of Reserves Deferred income taxes Increase (Decrease) in Deferred Income Taxes Revenues Revenue from Contract with Customer [Text Block] Customer E Customer E Represents information pertaining to the customer E. Average risk-free interest rates (as a percent) Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Associated future global development costs , if elected to co-develop (as a percent) Percentage Funding on Cost on Possible Election of Co-development of Compounds Represents the percentage of associated future global development costs from the initiation of a Phase IIb trial provided the entity elects to co-develop any compounds and/or indications. Amount recognized and received for the achievement of a predefined milestone License Agreement, Amount Recognized and Received for Achievement of a Predefined Milestone Represents the earning recognized and the payment received for the achievement of a predefined milestone under the license agreement. Tax withholdings related to restricted and performance share vesting Payment, Tax Withholding, Share-Based Payment Arrangement Total liabilities and stockholders’ equity Liabilities and Equity Royalties payable on net sales Increase (Decrease) in Royalties Payable Contractual maturity dates Debt Instrument, Term Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Land Land [Member] Dilutive stock options and awards ( in shares) Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements Diluted Net Income (Loss) Per Share Earnings Per Share, Diluted [Abstract] Non-US Non-US [Member] Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] ADSs ADSs Represents American Depositary Shares. Fair Value, Inputs, Level 2 Fair Value, Inputs, Level 2 [Member] Current Fiscal Year End Date Current Fiscal Year End Date Diluted net income (loss) Net Income (Loss) Available to Common Stockholders, Diluted Vesting [Axis] Vesting [Axis] Diluted (in USD per share) Diluted net income per share ( in USD per share) Earnings Per Share, Diluted Sale of Stock [Domain] Sale of Stock [Domain] Share-based Payment Arrangement, Tranche Two Share-Based Payment Arrangement, Tranche Two [Member] Effected stock split (as a percent) Stockholders' Equity Note, Stock Split, Conversion Ratio Vesting period Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period License Agreements License Agreements License Agreements Stock compensation APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Unrecognized compensation Share-Based Payment Arrangement, Additional Disclosure [Abstract] Concentration Risk Type [Axis] Concentration Risk Type [Axis] Total current liabilities Liabilities, Current Inventory, Current [Table] Inventory, Current [Table] Anti-dilutive securities Earnings Per Share, Diluted, Other Disclosure [Abstract] Customer Concentration Risk Customer Concentration Risk [Member] Common shares purchased (in shares) Equity Method Investment, Shares Purchased This element represents the aggregate shares purchased of investments accounted for under the equity method of accounting. Eli Lilly Eli Lilly Represents details pertaining to Eli Lilly with whom we have entered into a License, Development and Commercialization Agreement. License Agreements License Agreements [Text Block] This element may be used to describe all significant license agreements of the reporting entity. Issuance of shares of Common Stock for services rendered Stock Issued During Period, Shares, Issued for Services Stock option grant term Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period Unrealized loss on long term investments Unrealized loss on long term investments Unrealized gain (loss) on long term investments Equity Securities, FV-NI, Unrealized Gain (Loss) Entity Address, Address Line One Entity Address, Address Line One Cost of product revenues (including definite-lived intangible amortization) Cost of Revenue Innovent Innovent Represents details pertaining to Innovent Biologics, Inc with whom we have entered into a research collaboration and licensing agreement. Product and Service [Axis] Product and Service [Axis] Europe Europe [Member] Expected return on plan assets Defined Benefit Plan, Expected Return (Loss) on Plan Assets Schedule of RSU award and PSU activity under the 2010 Stock Plan Schedule of RSU award and PSU activity under the 2010 Stock Plan Tabular disclosure represents the schedule of share based compensation other than stock options activity. Customer A, B, C, D and E Customer A, B, C D, and E Represents information pertaining to the aggregate list of concentration customers. Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Interest expense Interest Expense Unrealized loss on marketable securities, net of tax OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax Inventory Inventories-noncurrent Inventory, Noncurrent Schedule of accrued and other current liabilities Schedule of Accrued Liabilities [Table Text Block] Inventory Inventory Disclosure [Text Block] Subsequent Event [Table] Subsequent Event [Table] Granted (in USD per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Intrinsic Value, Amount Per Share Assumed annualized forfeiture rate (as a percent) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions Expected Annualized Forfeiture Rate Represents the expected annualized forfeiture rate for options granted. Inventory Disclosure [Abstract] Inventory Disclosure [Abstract] Available Shares for Grant Share-Based Compensation Arrangement by Share-Based Payment Award, Additional General Disclosures [Abstract] Entity Tax Identification Number Entity Tax Identification Number RSU and PSU Grant Price Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value [Abstract] Summary of shares available for grant Schedule of Nonvested Share Activity [Table Text Block] Outstanding at the beginning of the period (in shares) Outstanding at the end of the period (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number Customer B Customer B [Member] Represents information pertaining to the customer B. Schedule of disaggregated revenue Disaggregation of Revenue [Table Text Block] Regulatory Milestones Regulatory Milestones Represents information pertaining to certain regulatory events on the basis of which certain milestones are achieved. Development Milestones Development Milestones Represents information pertaining to certain development events on the basis of which certain milestones are achieved. Revenue from Contract with Customer [Abstract] Revenue from Contract with Customer [Abstract] Number of programs under the resulting products are co-funded for development Number of Programs Under Which The Resulting Products Are Co-Funded For Development Represents the number of programs in which the resulting products are co-funded for development. Share price of shares available (in USD per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instrument Other than Option, Nonvested, Intrinsic Value Roll forward of Level 3 liabilities Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] MINJUVI MINJUVI Represents information pertaining to MONJUVI/MINJUVI (tafasitamab-cxix). Net increase in cash, cash equivalents, restricted cash and investments Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Milestone and contract revenues Milestone revenues Represents information pertaining to milestone revenue. Accrued Liabilities Accrued Liabilities [Member] Valuation input (as a percent) Business Combination, Contingent Consideration, Liability, Measurement Input OLUMIANT OLUMIANT Baricitinib for the treatment of moderate-to-severe rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to, one or more disease-modifying antirheumatic drugs (DMARDs). Other intangible assets, net Other Intangible Assets, Net Entity Central Index Key Entity Central Index Key Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] JAKAVI Royalty Revenues JAKAVI Royalty Revenues Represents information pertaining to JAKAVI royalty revenues, an oral Janus associate kinase (JAK) inhibitor sold within the United State of America. Measurement Frequency [Axis] Measurement Frequency [Axis] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Royalty-bearing product other than GITR, OX40 and one undisclosed target Royalty-bearing product other than GITR, OX40 and one undisclosed target Represents the royalty-bearing product other than GITR, OX40 and one undisclosed target. Measurement Input Type [Axis] Measurement Input Type [Axis] Entity [Domain] Entity [Domain] City Area Code City Area Code ASSETS Assets [Abstract] Retirement Benefits [Abstract] Retirement Benefits [Abstract] Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Sale of Stock [Axis] Sale of Stock [Axis] Cash flows from financing activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Total liabilities Financial Liabilities Fair Value Disclosure Schedule of concentration of credit risk related to collaborative partners Schedules of Concentration of Risk by Risk Factor Related to Collaborative Partners [Table Text Block] Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark, related to the collaborative partners. Stock-based compensation Share-Based Payment Arrangement, Noncash Expense Weighted-average fair value (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Collaboration loss sharing Collaboration Loss Sharing Expense The expense recognized during the reporting period for collaboration loss sharing. Other liabilities Other Liabilities, Noncurrent Research and Development Expense Research and Development Expense [Member] Merus Merus Represents information pertaining to Merus N. V. Revenues Disaggregation of Revenue [Line Items] Schedule of calculation of net income (loss) per share Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Purchase price of common stock Equity Method Investment, Aggregate Cost Equity Method Investment, Aggregate Cost Conversion of Stock, Name [Domain] Conversion of Stock, Name [Domain] Customer A Customer A [Member] Represents information pertaining to the customer A. Leased assets obtained in exchange for new operating lease liabilities Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Cost of Sales Cost of Sales [Member] Novartis Novartis Represents details pertaining to Novartis with whom we have entered into a Collaboration and License Agreement. Customer [Domain] Customer [Domain]